United States
Germany
Japan
United Kingdom
China
Aebp1 (NM_001100970) Rat Tagged ORF Clone Lentiviral Particle
CAT＃: RR200750L3V
- LentiORF®
-
Lenti ORF particles, Aebp1 (Myc-DDK-tagged ORF) - Rat AE binding protein 1 (Aebp1), 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 19,893.00
货期*
详询
规格
Product images
经常一起买 (2)
Specifications
| Product Data | |
| Product Name | Aebp1 (NM_001100970) Rat Tagged ORF Clone Lentiviral Particle |
| Vector | pLenti-C-Myc-DDK-P2A-Puro |
| ACCN | NM_001100970 |
| ORF Size | 3384 bp |
| Sequence Data |
The ORF insert of this clone is exactly the same as(RR200750).
|
| OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
| OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
| Reference Data | |
| RefSeq | NM_001100970.1, NP_001094440.1 |
| RefSeq Size | 3817 bp |
| RefSeq ORF | 3387 bp |
| Locus ID | 305494 |
| Gene Summary | As a positive regulator of collagen fibrillogenesis, it is probably involved in the organization and remodeling of the extracellualr matrix (By similarity). May positively regulate MAP-kinase activity in adipocytes, leading to enhanced adipocyte proliferation and reduced adipocyte differentiation. May also positively regulate NF-kappa-B activity in macrophages by promoting the phosphorylation and subsequent degradation of I-kappa-B-alpha (NFKBIA), leading to enhanced macrophage inflammatory responsiveness. Can act as a transcriptional repressor.[UniProtKB/Swiss-Prot Function] |
Documents
| Product Manuals |
| FAQs |
| SDS |
Resources
You may also need
Customer
Reviews
Loading...
